Business Description
Aurobindo Pharma Ltd
SIC : 2833
ISIN : INE406A01037
Share Class Description:
BOM:524804: Ordinary SharesTotal Employee Number:
46,455Compare
Compare
Traded in other countries / regions
AUROPHARMA.India IPO Date
1995-04-10Description
Aurobindo Pharma Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and marketing of generic pharmaceuticals, active pharmaceutical ingredients (APIs), and specialty drugs. Its formulations portfolio spans therapeutic areas including central nervous system, antibiotics, anti-diabetics, cardiovascular, anti-retrovirals, gastroenterology, oncology, and dermatology. The company also produces APIs and intermediates, which it supplies both for its own formulations and to third parties. Aurobindo sells through its own marketing arms and through partnerships and distribution agreements with generic drug companies, particularly in the United States, where it maintains a large share of its business. Its operations are organized around geographic segments covering India, the United States, Europe, and the rest of the world, with the United States representing the largest revenue contributor. The company operates manufacturing facilities in India and other locations, and its revenue derives mainly from generic product sales, API supply, and related contract services.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.31 | |||||
Equity-to-Asset | 0.65 | |||||
Debt-to-Equity | 0.21 | |||||
Debt-to-EBITDA | 1.05 | |||||
Interest Coverage | 13.6 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 4.84 | |||||
Beneish M-Score | -2.5 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11 | |||||
3-Year EBITDA Growth Rate | 22.3 | |||||
3-Year EPS without NRI Growth Rate | 23.7 | |||||
3-Year Book Growth Rate | 12.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 18.16 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 11.99 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 75.06 | |||||
9-Day RSI | 68.45 | |||||
14-Day RSI | 64.96 | |||||
3-1 Month Momentum % | 13.54 | |||||
6-1 Month Momentum % | 29.11 | |||||
12-1 Month Momentum % | 45.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.81 | |||||
Quick Ratio | 1.15 | |||||
Cash Ratio | 0.59 | |||||
Days Inventory | 296.26 | |||||
Days Sales Outstanding | 65.68 | |||||
Days Payable | 127.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.23 | |||||
Dividend Payout Ratio | 0.06 | |||||
3-Year Dividend Growth Rate | -18.9 | |||||
5-Year Yield-on-Cost % | 0.23 | |||||
3-Year Average Share Buyback Ratio | 0.3 | |||||
Shareholder Yield % | 0.67 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 60.01 | |||||
Operating Margin % | 15.2 | |||||
Net Margin % | 10.7 | |||||
EBITDA Margin % | 22.1 | |||||
FCF Margin % | 8.09 | |||||
OCF Margin % | 15.78 | |||||
ROE % | 10.55 | |||||
ROA % | 6.93 | |||||
ROIC % | 9.35 | |||||
3-Year ROIIC % | 13.96 | |||||
ROC (Joel Greenblatt) % | 21.55 | |||||
ROCE % | 15.47 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 27.18 | |||||
Forward PE Ratio | 21.79 | |||||
PE Ratio without NRI | 26.66 | |||||
Shiller PE Ratio | 25.92 | |||||
Price-to-Owner-Earnings | 27.67 | |||||
PEG Ratio | 8.89 | |||||
PS Ratio | 2.91 | |||||
PB Ratio | 2.66 | |||||
Price-to-Tangible-Book | 3.1 | |||||
Price-to-Free-Cash-Flow | 41.73 | |||||
Price-to-Operating-Cash-Flow | 18.28 | |||||
EV-to-EBIT | 16.75 | |||||
EV-to-Forward-EBIT | 6.48 | |||||
EV-to-EBITDA | 12.68 | |||||
EV-to-Forward-EBITDA | 4.87 | |||||
EV-to-Revenue | 2.8 | |||||
EV-to-Forward-Revenue | 0.88 | |||||
EV-to-FCF | 38.87 | |||||
Price-to-GF-Value | 1.21 | |||||
Price-to-Projected-FCF | 2.27 | |||||
Price-to-DCF (Earnings Based) | 2.67 | |||||
Price-to-DCF (FCF Based) | 4.18 | |||||
Price-to-Median-PS-Value | 1.34 | |||||
Price-to-Peter-Lynch-Fair-Value | 3.04 | |||||
Price-to-Graham-Number | 1.98 | |||||
| Price-to-Net-Current-Asset-Value | 8.35 | |||||
Earnings Yield (Greenblatt) % | 5.98 | |||||
FCF Yield % | 2.44 | |||||
Forward Rate of Return (Yacktman) % | 4.08 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aurobindo Pharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 349,352.9 | ||
| EPS (TTM) (₹) | 64.003 | ||
| Beta | 0.6776 | ||
| 3-Year Sharpe Ratio | 0.75 | ||
| 3-Year Sortino Ratio | 1.26 | ||
| Volatility % | 13.16 | ||
| 14-Day RSI | 64.96 | ||
| 14-Day ATR (₹) | 41.268394 | ||
| 20-Day SMA (₹) | 1657.435 | ||
| 12-1 Month Momentum % | 45.19 | ||
| 52-Week Range (₹) | 1066 - 1735 | ||
| Shares Outstanding (Mil) | 575.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aurobindo Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aurobindo Pharma Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2027 | 2027-02-10 08:30 | In 142 days | ||
| Third quarter earnings results for 2027 | 2027-02-09 | In 140 days | ||
| Second quarter earnings conference call for 2027 | 2026-11-06 08:30 | In 46 days | ||
| Second quarter earnings results for 2027 | 2026-11-06 | In 45 days | ||
| General meeting for 2026 | 2026-08-27 15:30 | 1,622.00 (+0.98%) | ||
| First quarter earnings conference call for 2027 | 2026-08-06 08:30 | 1,613.40 (+0.82%) | ||
| First quarter earnings results for 2027 | 2026-08-06 | 1,613.40 (+0.82%) | ||
| Annual report for 2026 | 2026-08-03 | 1,579.35 (-0.55%) | ||
| Fourth quarter earnings conference call for 2026 | 2026-05-22 08:30 | 1,546.45 (+1.73%) | ||
| Fourth quarter earnings results for 2026 | 2026-05-22 | 1,546.45 (+1.73%) |
Show
Entries
Aurobindo Pharma Ltd Frequently Asked Questions
What is Aurobindo Pharma Ltd(BOM:524804)'s stock price today?
The current price of BOM:524804 is ₹1717.20. The 52 week high of BOM:524804 is ₹1735.00 and 52 week low is ₹1066.00.
When is next earnings date of Aurobindo Pharma Ltd(BOM:524804)?
The next earnings date of Aurobindo Pharma Ltd(BOM:524804) is 2026-11-06 Est..
Does Aurobindo Pharma Ltd(BOM:524804) pay dividends? If so, how much?
The Dividend Yield %  of Aurobindo Pharma Ltd(BOM:524804) is 0.23% (As of Today), Highest Dividend Payout Ratio of Aurobindo Pharma Ltd(BOM:524804) was 0.23. The lowest was 0.05. And the median was 0.08. The  Forward Dividend Yield % of Aurobindo Pharma Ltd(BOM:524804) is 0%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Aurobindo Pharma Wins Company of the Year and Acquisition of the Year Awards at the Global Generics & Biosimilars Awards 2019 | 2019-11-21 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers